Top Story

Breast cancer risk, breast density useful in guiding mammogram frequency

August 24, 2016

Tailoring mammography screening intervals to each patient will help in maximizing benefits and minimizing harms, according to findings published in the Annals of Internal Medicine.

Researchers found that women with average breast cancer risk and low breast density should have mammograms every 3 years, while women with higher risk and high breast density should be screened yearly.

Bayer awards grants for research into hemophilia, bleeding disorders

August 24, 2016
Bayer awarded six grants to U.S. clinicians and investigators for research and educational initiatives in hemophilia and related bleeding disorders. The recipients are…
FDA News

FDA grants breakthrough therapy designation to SL-401

August 24, 2016
The FDA granted breakthrough therapy designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm. SL-401 (Stemline Therapeutics) — a…
In the Journals Plus

rVIII-SingleChain appears safe, effective for severe hemophilia A

August 24, 2016
The novel therapy rVIII-SingleChain demonstrated hemostatic efficacy in surgery and controlled bleeding events in patients with severe hemophilia A, according to…
In the Journals Plus

Plasma analysis shows promise for NSCLC T790M genotyping

August 23, 2016
Patients with T790M–positive advanced non–small cell lung cancer demonstrated similar outcomes with osimertinib whether the T790M mutation was detected…
More News Headlines »

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Meeting News Coverage

VIDEO: Neratinib benefits patients with HER-2–negative breast cancer

August 20, 2016
More »
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer


Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Current Issues
View the Current Issue
HemOnc Today